Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs

Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic 18 F-pretomanid positron emission tomogra...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 15; no. 1; pp. 6657 - 11
Main Authors Chen, Xueyi, Arun, Bhavatharini, Nino-Meza, Oscar J., Sarhan, Mona O., Singh, Medha, Jeon, Byeonghoon, Mane, Kishor, Shah, Maunank, Tucker, Elizabeth W., Carroll, Laurence S., Freundlich, Joel S., Peloquin, Charles A., Ivaturi, Vijay D., Jain, Sanjay K.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 14.08.2024
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic 18 F-pretomanid positron emission tomography (PET) in eight human subjects to visualize 18 F-pretomanid biodistribution as concentration-time exposures in multiple compartments (NCT05609552), demonstrating preferential brain versus lung tissue partitioning. Preferential, antibiotic-specific partitioning into brain or lung tissues of several antibiotics, active against multidrug resistant (MDR) Mycobacterium tuberculosis  strains, are confirmed in experimentally-infected mice and rabbits, using dynamic PET with chemically identical antibiotic radioanalogs, and postmortem mass spectrometry measurements. PET-facilitated pharmacokinetic modeling predicts human dosing necessary to attain therapeutic brain exposures. These data are used to design optimized, pretomanid-based regimens which are evaluated at human equipotent dosing in a mouse model of TB meningitis, demonstrating excellent bactericidal activity without an increase in intracerebral inflammation or brain injury. Importantly, several antibiotic regimens demonstrate discordant activities in brain and lung tissues in the same animal, correlating with tissue antibiotic exposures. These data provide a mechanistic basis for the compartmentalized activities of antibiotic regimens, with important implications for developing treatments for meningitis and other infections in compartments with unique antibiotic penetration. Antibiotic treatments for tuberculous meningitis, the deadliest form of tuberculosis, are not optimized. Here, PET in human and animal studies is used to measure the biodistribution of several antibiotics to develop optimized regimens for drug-resistant tuberculous meningitis.
AbstractList Abstract Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic 18F-pretomanid positron emission tomography (PET) in eight human subjects to visualize 18F-pretomanid biodistribution as concentration-time exposures in multiple compartments (NCT05609552), demonstrating preferential brain versus lung tissue partitioning. Preferential, antibiotic-specific partitioning into brain or lung tissues of several antibiotics, active against multidrug resistant (MDR) Mycobacterium tuberculosis strains, are confirmed in experimentally-infected mice and rabbits, using dynamic PET with chemically identical antibiotic radioanalogs, and postmortem mass spectrometry measurements. PET-facilitated pharmacokinetic modeling predicts human dosing necessary to attain therapeutic brain exposures. These data are used to design optimized, pretomanid-based regimens which are evaluated at human equipotent dosing in a mouse model of TB meningitis, demonstrating excellent bactericidal activity without an increase in intracerebral inflammation or brain injury. Importantly, several antibiotic regimens demonstrate discordant activities in brain and lung tissues in the same animal, correlating with tissue antibiotic exposures. These data provide a mechanistic basis for the compartmentalized activities of antibiotic regimens, with important implications for developing treatments for meningitis and other infections in compartments with unique antibiotic penetration.
Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic 18F-pretomanid positron emission tomography (PET) in eight human subjects to visualize 18F-pretomanid biodistribution as concentration-time exposures in multiple compartments (NCT05609552), demonstrating preferential brain versus lung tissue partitioning. Preferential, antibiotic-specific partitioning into brain or lung tissues of several antibiotics, active against multidrug resistant (MDR) Mycobacterium tuberculosis strains, are confirmed in experimentally-infected mice and rabbits, using dynamic PET with chemically identical antibiotic radioanalogs, and postmortem mass spectrometry measurements. PET-facilitated pharmacokinetic modeling predicts human dosing necessary to attain therapeutic brain exposures. These data are used to design optimized, pretomanid-based regimens which are evaluated at human equipotent dosing in a mouse model of TB meningitis, demonstrating excellent bactericidal activity without an increase in intracerebral inflammation or brain injury. Importantly, several antibiotic regimens demonstrate discordant activities in brain and lung tissues in the same animal, correlating with tissue antibiotic exposures. These data provide a mechanistic basis for the compartmentalized activities of antibiotic regimens, with important implications for developing treatments for meningitis and other infections in compartments with unique antibiotic penetration.Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic 18F-pretomanid positron emission tomography (PET) in eight human subjects to visualize 18F-pretomanid biodistribution as concentration-time exposures in multiple compartments (NCT05609552), demonstrating preferential brain versus lung tissue partitioning. Preferential, antibiotic-specific partitioning into brain or lung tissues of several antibiotics, active against multidrug resistant (MDR) Mycobacterium tuberculosis strains, are confirmed in experimentally-infected mice and rabbits, using dynamic PET with chemically identical antibiotic radioanalogs, and postmortem mass spectrometry measurements. PET-facilitated pharmacokinetic modeling predicts human dosing necessary to attain therapeutic brain exposures. These data are used to design optimized, pretomanid-based regimens which are evaluated at human equipotent dosing in a mouse model of TB meningitis, demonstrating excellent bactericidal activity without an increase in intracerebral inflammation or brain injury. Importantly, several antibiotic regimens demonstrate discordant activities in brain and lung tissues in the same animal, correlating with tissue antibiotic exposures. These data provide a mechanistic basis for the compartmentalized activities of antibiotic regimens, with important implications for developing treatments for meningitis and other infections in compartments with unique antibiotic penetration.
Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic F-pretomanid positron emission tomography (PET) in eight human subjects to visualize F-pretomanid biodistribution as concentration-time exposures in multiple compartments (NCT05609552), demonstrating preferential brain versus lung tissue partitioning. Preferential, antibiotic-specific partitioning into brain or lung tissues of several antibiotics, active against multidrug resistant (MDR) Mycobacterium tuberculosis strains, are confirmed in experimentally-infected mice and rabbits, using dynamic PET with chemically identical antibiotic radioanalogs, and postmortem mass spectrometry measurements. PET-facilitated pharmacokinetic modeling predicts human dosing necessary to attain therapeutic brain exposures. These data are used to design optimized, pretomanid-based regimens which are evaluated at human equipotent dosing in a mouse model of TB meningitis, demonstrating excellent bactericidal activity without an increase in intracerebral inflammation or brain injury. Importantly, several antibiotic regimens demonstrate discordant activities in brain and lung tissues in the same animal, correlating with tissue antibiotic exposures. These data provide a mechanistic basis for the compartmentalized activities of antibiotic regimens, with important implications for developing treatments for meningitis and other infections in compartments with unique antibiotic penetration.
Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic 18F-pretomanid positron emission tomography (PET) in eight human subjects to visualize 18F-pretomanid biodistribution as concentration-time exposures in multiple compartments (NCT05609552), demonstrating preferential brain versus lung tissue partitioning. Preferential, antibiotic-specific partitioning into brain or lung tissues of several antibiotics, active against multidrug resistant (MDR) Mycobacterium tuberculosis strains, are confirmed in experimentally-infected mice and rabbits, using dynamic PET with chemically identical antibiotic radioanalogs, and postmortem mass spectrometry measurements. PET-facilitated pharmacokinetic modeling predicts human dosing necessary to attain therapeutic brain exposures. These data are used to design optimized, pretomanid-based regimens which are evaluated at human equipotent dosing in a mouse model of TB meningitis, demonstrating excellent bactericidal activity without an increase in intracerebral inflammation or brain injury. Importantly, several antibiotic regimens demonstrate discordant activities in brain and lung tissues in the same animal, correlating with tissue antibiotic exposures. These data provide a mechanistic basis for the compartmentalized activities of antibiotic regimens, with important implications for developing treatments for meningitis and other infections in compartments with unique antibiotic penetration.Antibiotic treatments for tuberculous meningitis, the deadliest form of tuberculosis, are not optimized. Here, PET in human and animal studies is used to measure the biodistribution of several antibiotics to develop optimized regimens for drug-resistant tuberculous meningitis.
Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those developed for pulmonary TB and not optimized for brain penetration. Here, we perform first-in-human dynamic 18 F-pretomanid positron emission tomography (PET) in eight human subjects to visualize 18 F-pretomanid biodistribution as concentration-time exposures in multiple compartments (NCT05609552), demonstrating preferential brain versus lung tissue partitioning. Preferential, antibiotic-specific partitioning into brain or lung tissues of several antibiotics, active against multidrug resistant (MDR) Mycobacterium tuberculosis  strains, are confirmed in experimentally-infected mice and rabbits, using dynamic PET with chemically identical antibiotic radioanalogs, and postmortem mass spectrometry measurements. PET-facilitated pharmacokinetic modeling predicts human dosing necessary to attain therapeutic brain exposures. These data are used to design optimized, pretomanid-based regimens which are evaluated at human equipotent dosing in a mouse model of TB meningitis, demonstrating excellent bactericidal activity without an increase in intracerebral inflammation or brain injury. Importantly, several antibiotic regimens demonstrate discordant activities in brain and lung tissues in the same animal, correlating with tissue antibiotic exposures. These data provide a mechanistic basis for the compartmentalized activities of antibiotic regimens, with important implications for developing treatments for meningitis and other infections in compartments with unique antibiotic penetration. Antibiotic treatments for tuberculous meningitis, the deadliest form of tuberculosis, are not optimized. Here, PET in human and animal studies is used to measure the biodistribution of several antibiotics to develop optimized regimens for drug-resistant tuberculous meningitis.
ArticleNumber 6657
Author Peloquin, Charles A.
Arun, Bhavatharini
Singh, Medha
Carroll, Laurence S.
Mane, Kishor
Nino-Meza, Oscar J.
Sarhan, Mona O.
Ivaturi, Vijay D.
Jain, Sanjay K.
Freundlich, Joel S.
Shah, Maunank
Jeon, Byeonghoon
Chen, Xueyi
Tucker, Elizabeth W.
Author_xml – sequence: 1
  givenname: Xueyi
  orcidid: 0000-0003-1574-7759
  surname: Chen
  fullname: Chen, Xueyi
  organization: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine
– sequence: 2
  givenname: Bhavatharini
  surname: Arun
  fullname: Arun, Bhavatharini
  organization: Center for Translational Medicine, University of Maryland School of Pharmacy
– sequence: 3
  givenname: Oscar J.
  surname: Nino-Meza
  fullname: Nino-Meza, Oscar J.
  organization: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine
– sequence: 4
  givenname: Mona O.
  surname: Sarhan
  fullname: Sarhan, Mona O.
  organization: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine
– sequence: 5
  givenname: Medha
  surname: Singh
  fullname: Singh, Medha
  organization: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine
– sequence: 6
  givenname: Byeonghoon
  orcidid: 0009-0008-3993-6486
  surname: Jeon
  fullname: Jeon, Byeonghoon
  organization: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine
– sequence: 7
  givenname: Kishor
  surname: Mane
  fullname: Mane, Kishor
  organization: Department of Pharmacology, Physiology, and Neuroscience, Rutgers New Jersey Medical School
– sequence: 8
  givenname: Maunank
  surname: Shah
  fullname: Shah, Maunank
  organization: Department of Medicine, Johns Hopkins University School of Medicine
– sequence: 9
  givenname: Elizabeth W.
  surname: Tucker
  fullname: Tucker, Elizabeth W.
  organization: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine
– sequence: 10
  givenname: Laurence S.
  surname: Carroll
  fullname: Carroll, Laurence S.
  organization: Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine
– sequence: 11
  givenname: Joel S.
  orcidid: 0000-0002-3411-3455
  surname: Freundlich
  fullname: Freundlich, Joel S.
  organization: Department of Pharmacology, Physiology, and Neuroscience, Rutgers New Jersey Medical School
– sequence: 12
  givenname: Charles A.
  orcidid: 0000-0001-9002-7052
  surname: Peloquin
  fullname: Peloquin, Charles A.
  organization: Infectious Disease Pharmacokinetics Laboratory, Pharmacotherapy and Translational Research, University of Florida College of Pharmacy
– sequence: 13
  givenname: Vijay D.
  orcidid: 0000-0002-6433-1154
  surname: Ivaturi
  fullname: Ivaturi, Vijay D.
  organization: Center for Translational Medicine, University of Maryland School of Pharmacy, Centre for Pharmacometrics, Manipal University
– sequence: 14
  givenname: Sanjay K.
  orcidid: 0000-0001-9620-7070
  surname: Jain
  fullname: Jain, Sanjay K.
  email: sjain5@jhmi.edu
  organization: Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Department of Pediatrics, Johns Hopkins University School of Medicine, Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39143055$$D View this record in MEDLINE/PubMed
BookMark eNp9Ustu1TAUjFARfdAfYIEisWET8CtxskKotFCpEizK2vLjJPgqsS9-VC1fj2_TQttFvfGxPTOaOceH1Z7zDqrqDUYfMKL9x8gw63iDCGtaNPRDw15UBwQx3GBO6N6Der86jnGDyqID7hl7Ve2XglHUtgfV-OXGycXq-sfpZR3gCuQca-2XrQxpAZfkbP-AqVWQ1tXSmXrObqqTjTFDOSerrE-FDtdbH3OAWPuxTllB0Hn20cbahDzF19XLsSjD8d1-VP08O708-dZcfP96fvL5otEtw6mRQEbSaoYAjGlNR2WvFSOIG8RRZ4jWaCBYG86RJIaw0Qy003ToJSjSd5IeVeerrvFyI7bBLjLcCC-tuL3wYRIlmNUzCEwUZxwIV6WHijI5Kmg5x6rf9RepovVp1dpmtYDRpRtBzo9EH784-0tM_kpgTAkbUFcU3t8pBP87Q0xisVHDPEsHPkdB0UDLhBhvC_TdE-jG5-BKr3YoMpTEPS-otw8t_fNyP88C6FeADj7GAKPQNslk_c6hnQVGYpdOrL9HlOTi9vcIVqjkCfVe_VkSXUmxgN0E4b_tZ1h_AQRR2Bo
CitedBy_id crossref_primary_10_3390_vaccines12121397
Cites_doi 10.7554/eLife.85307
10.1128/AAC.01691-15
10.1371/journal.pone.0094462
10.1128/AAC.00021-19
10.3389/fphar.2022.1048653
10.1371/journal.pone.0105222
10.1136/jnnp.53.1.81
10.1002/cpt.646
10.1007/s40265-019-01207-9
10.1186/s13063-022-06772-1
10.1016/j.ijantimicag.2023.107048
10.1128/AAC.01354-09
10.1186/s12941-015-0107-z
10.1128/aac.00658-22
10.2967/jnumed.117.207431
10.1056/NEJMoa040573
10.1016/j.tube.2010.07.002
10.1126/scitranslmed.aau0965
10.1038/s41573-020-0080-x
10.1371/journal.pone.0270201
10.1093/cid/cix540
10.1517/17425255.2013.786042
10.1093/cid/cix230
10.1038/nrneurol.2017.120
10.1038/s41590-018-0119-x
10.1177/074823379701300401
10.1016/S1474-4422(21)00435-X
10.1128/AAC.00106-09
10.1021/acsinfecdis.9b00473
10.1038/s41591-020-0770-2
10.1111/bcp.15102
10.1128/aac.00035-23
10.1093/infdis/jit331
10.1128/AAC.01644-12
10.1172/JCI155851
10.12688/wellcomeopenres.16783.1
10.1172/JCI145107
10.1086/605576
10.1371/journal.pone.0133869
10.1128/AAC.05293-11
10.1128/AAC.04180-14
10.3390/pharmaceutics16010144
10.1007/s40262-023-01217-7
10.1056/NEJMoa1507062
10.1128/AAC.01182-08
10.1038/s41467-022-35730-3
10.1128/AAC.48.5.1441-1453.2004
10.1097/00006454-199203000-00004
10.1021/acsinfecdis.9b00207
10.1021/jm901858n
10.1016/j.resuscitation.2022.02.024
10.1128/AAC.00849-10
10.1093/cid/ciw763
10.1007/s40262-024-01363-6
ContentType Journal Article
Copyright The Author(s) 2024
2024. The Author(s).
The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2024 2024
Copyright_xml – notice: The Author(s) 2024
– notice: 2024. The Author(s).
– notice: The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2024 2024
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7T7
7TM
7TO
7X7
7XB
88E
8AO
8FD
8FE
8FG
8FH
8FI
8FJ
8FK
ABUWG
AEUYN
AFKRA
ARAPS
AZQEC
BBNVY
BENPR
BGLVJ
BHPHI
C1K
CCPQU
DWQXO
FR3
FYUFA
GHDGH
GNUQQ
H94
HCIFZ
K9.
LK8
M0S
M1P
M7P
P5Z
P62
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQQKQ
PQUKI
RC3
SOI
7X8
5PM
DOA
DOI 10.1038/s41467-024-50989-4
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Bacteriology Abstracts (Microbiology B)
Calcium & Calcified Tissue Abstracts
Chemoreception Abstracts
Ecology Abstracts
Entomology Abstracts (Full archive)
Environment Abstracts
Immunology Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
Nucleic Acids Abstracts
Oncogenes and Growth Factors Abstracts
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Pharma Collection
Technology Research Database
ProQuest SciTech Collection
ProQuest Technology Collection
ProQuest Natural Science Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest One Sustainability
ProQuest Central UK/Ireland
Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Technology Collection
ProQuest Natural Science Collection
Environmental Sciences and Pollution Management
ProQuest One
ProQuest Central
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
AIDS and Cancer Research Abstracts
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni)
Medical Database
Biological Science Database
Advanced Technologies & Aerospace Database
ProQuest Advanced Technologies & Aerospace Collection
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
Genetics Abstracts
Environment Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Advanced Technologies & Aerospace Collection
ProQuest Central Essentials
Nucleic Acids Abstracts
SciTech Premium Collection
Environmental Sciences and Pollution Management
ProQuest One Applied & Life Sciences
ProQuest One Sustainability
Health Research Premium Collection
Natural Science Collection
Health & Medical Research Collection
Biological Science Collection
Chemoreception Abstracts
Industrial and Applied Microbiology Abstracts (Microbiology A)
ProQuest Central (New)
ProQuest Medical Library (Alumni)
Advanced Technologies & Aerospace Collection
ProQuest Biological Science Collection
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
ProQuest Technology Collection
Health Research Premium Collection (Alumni)
Biological Science Database
Ecology Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Entomology Abstracts
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
Engineering Research Database
ProQuest One Academic
Calcium & Calcified Tissue Abstracts
ProQuest One Academic (New)
Technology Collection
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Natural Science Collection
ProQuest Pharma Collection
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Bacteriology Abstracts (Microbiology B)
AIDS and Cancer Research Abstracts
ProQuest SciTech Collection
Advanced Technologies & Aerospace Database
ProQuest Medical Library
Immunology Abstracts
Environment Abstracts
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
MEDLINE
Publicly Available Content Database


Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: 8FG
  name: ProQuest Technology Collection
  url: https://search.proquest.com/technologycollection1
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2041-1723
EndPage 11
ExternalDocumentID oai_doaj_org_article_12b747e27b024b34afbe5771b810380b
PMC11324906
39143055
10_1038_s41467_024_50989_4
Genre Journal Article
Observational Study
GrantInformation_xml – fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
– fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  grantid: R01-AI145435-A1; R01-AI153349; R21- AI149760; K08-AI139371
  funderid: https://doi.org/10.13039/100000060
– fundername: U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
  grantid: R01-HL131829
  funderid: https://doi.org/10.13039/100000050
– fundername: NIAID NIH HHS
  grantid: R01 AI153349
– fundername: U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)
  grantid: R01-HL131829
– fundername: NIAID NIH HHS
  grantid: R01 AI145435
– fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  grantid: R01-AI153349
– fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  grantid: R21- AI149760
– fundername: NIAID NIH HHS
  grantid: K08 AI139371
– fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  grantid: K08-AI139371
– fundername: NHLBI NIH HHS
  grantid: R01 HL131829
– fundername: NIAID NIH HHS
  grantid: R21 AI149760
– fundername: U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  grantid: R01-AI145435-A1
GroupedDBID ---
0R~
39C
3V.
53G
5VS
70F
7X7
88E
8AO
8FE
8FG
8FH
8FI
8FJ
AAHBH
AAJSJ
ABUWG
ACGFO
ACGFS
ACIWK
ACMJI
ACPRK
ACSMW
ADBBV
ADFRT
ADMLS
ADRAZ
AENEX
AEUYN
AFKRA
AFRAH
AHMBA
AJTQC
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMTXH
AOIJS
ARAPS
ASPBG
AVWKF
AZFZN
BBNVY
BCNDV
BENPR
BGLVJ
BHPHI
BPHCQ
BVXVI
C6C
CCPQU
DIK
EBLON
EBS
EE.
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
HCIFZ
HMCUK
HVGLF
HYE
HZ~
KQ8
LGEZI
LK8
LOTEE
M1P
M48
M7P
M~E
NADUK
NAO
NXXTH
O9-
OK1
P2P
P62
PIMPY
PQQKQ
PROAC
PSQYO
RNS
RNT
RNTTT
RPM
SNYQT
SV3
TSG
UKHRP
AASML
AAYXX
CITATION
PHGZM
PHGZT
CGR
CUY
CVF
ECM
EIF
NPM
7QL
7QP
7QR
7SN
7SS
7ST
7T5
7T7
7TM
7TO
7XB
8FD
8FK
AARCD
AZQEC
C1K
DWQXO
FR3
GNUQQ
H94
K9.
P64
PJZUB
PKEHL
PPXIY
PQEST
PQGLB
PQUKI
RC3
SOI
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c541t-ae2f25c40eedd5d63a8cb4207d0706d2cc0921cd770a2d24fd936c398aeb286a3
IEDL.DBID M48
ISSN 2041-1723
IngestDate Wed Aug 27 01:27:19 EDT 2025
Thu Aug 21 18:34:53 EDT 2025
Mon Jul 21 10:02:04 EDT 2025
Wed Aug 13 07:37:08 EDT 2025
Wed Feb 19 02:09:53 EST 2025
Thu Apr 24 23:04:16 EDT 2025
Tue Jul 01 02:37:27 EDT 2025
Fri Feb 21 02:39:59 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c541t-ae2f25c40eedd5d63a8cb4207d0706d2cc0921cd770a2d24fd936c398aeb286a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ORCID 0000-0002-6433-1154
0000-0001-9620-7070
0000-0001-9002-7052
0000-0002-3411-3455
0000-0003-1574-7759
0009-0008-3993-6486
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1038/s41467-024-50989-4
PMID 39143055
PQID 3092977087
PQPubID 546298
PageCount 11
ParticipantIDs doaj_primary_oai_doaj_org_article_12b747e27b024b34afbe5771b810380b
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11324906
proquest_miscellaneous_3093172475
proquest_journals_3092977087
pubmed_primary_39143055
crossref_citationtrail_10_1038_s41467_024_50989_4
crossref_primary_10_1038_s41467_024_50989_4
springer_journals_10_1038_s41467_024_50989_4
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-08-14
PublicationDateYYYYMMDD 2024-08-14
PublicationDate_xml – month: 08
  year: 2024
  text: 2024-08-14
  day: 14
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Nature communications
PublicationTitleAbbrev Nat Commun
PublicationTitleAlternate Nat Commun
PublicationYear 2024
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References Brown, Delp, Lindstedt, Rhomberg, Beliles (CR56) 1997; 13
Mota (CR7) 2022; 13
Whitfield (CR41) 2015; 10
Tucker (CR53) 2018; 10
CR39
Tasneen (CR54) 2011; 55
CR38
Lappin, Noveck, Burt (CR48) 2013; 9
Evans (CR26) 2022; 17
Tucker (CR21) 2024; 63
Ordonez (CR8) 2020; 26
Foss (CR51) 2018; 59
Ding (CR46) 2022; 66
Keam (CR10) 2019; 79
Foss, Harper, Wang, Pomper, Jain (CR11) 2013; 208
Vinnard (CR24) 2017; 64
Mehta, Guo, van der Graaf, van Hasselt (CR55) 2023; 62
Maranchick (CR37) 2022; 13
Wilkinson (CR4) 2017; 13
Tasneen (CR59) 2016; 60
Ordonez (CR6) 2021; 131
Xu (CR20) 2019; 63
Donald (CR31) 2010; 90
CR9
Ardiansyah (CR43) 2023; 12
Williams (CR61) 2009; 53
Heemskerk, Bang, Thwaites (CR42) 2016; 374
CR40
Wihersaari (CR44) 2022; 174
Ruiz-Bedoya (CR14) 2022; 132
Alffenaar (CR36) 2009; 49
Lakshminarayana (CR58) 2014; 9
Tietjen, Kroemer, Cattaneo, Baldelli, Wicha (CR57) 2022; 88
Maitre (CR17) 2022; 23
Mota (CR15) 2020; 6
Dong (CR32) 2024; 16
Torok (CR33) 2018; 103
Huynh (CR5) 2022; 21
Wallis (CR60) 2014; 9
Liu (CR35) 2010; 53
Weinstein (CR52) 2012; 56
Senbayrak (CR23) 2015; 14
Heemskerk (CR25) 2017; 65
CR50
Thwaites (CR19) 2004; 351
Diacon (CR27) 2010; 54
Li (CR47) 2023; 67
Ordonez (CR13) 2015; 59
Ordonez (CR16) 2019; 5
Ahmad (CR28) 2011; 55
Burt (CR49) 2020; 19
Jacobs, Sunakorn, Chotpitayasunonah, Pope, Kelleher (CR34) 1992; 11
Phuapradit, Supmonchai, Kaojarern, Mokkhavesa (CR30) 1990; 53
CR22
Davis (CR18) 2021; 6
Jain (CR3) 2018; 19
Rohlwink (CR45) 2017; 65
Muller, dela Pena, Derendorf (CR2) 2004; 48
Foss (CR12) 2018; 59
Ehrlich (CR1) 1913; 2
Ginsberg, Laurenzi, Rouse, Whitney, Spigelman (CR29) 2009; 53
AG Davis (50989_CR18) 2021; 6
50989_CR22
SB Lakshminarayana (50989_CR58) 2014; 9
S Dong (50989_CR32) 2024; 16
AA Ordonez (50989_CR8) 2020; 26
K Mehta (50989_CR55) 2023; 62
CA Foss (50989_CR12) 2018; 59
AA Ordonez (50989_CR13) 2015; 59
RS Wallis (50989_CR60) 2014; 9
PR Donald (50989_CR31) 2010; 90
SY Li (50989_CR47) 2023; 67
T Burt (50989_CR49) 2020; 19
RP Brown (50989_CR56) 1997; 13
AA Ordonez (50989_CR6) 2021; 131
C Vinnard (50989_CR24) 2017; 64
R Tasneen (50989_CR54) 2011; 55
E Ardiansyah (50989_CR43) 2023; 12
F Mota (50989_CR15) 2020; 6
S Senbayrak (50989_CR23) 2015; 14
EW Tucker (50989_CR21) 2024; 63
RJ Wilkinson (50989_CR4) 2017; 13
GE Thwaites (50989_CR19) 2004; 351
CA Foss (50989_CR51) 2018; 59
50989_CR50
SJ Keam (50989_CR10) 2019; 79
J Xu (50989_CR20) 2019; 63
T Maitre (50989_CR17) 2022; 23
CA Ruiz-Bedoya (50989_CR14) 2022; 132
R Tasneen (50989_CR59) 2016; 60
AK Tietjen (50989_CR57) 2022; 88
L Liu (50989_CR35) 2010; 53
50989_CR40
P Ehrlich (50989_CR1) 1913; 2
Y Ding (50989_CR46) 2022; 66
J Huynh (50989_CR5) 2022; 21
EA Weinstein (50989_CR52) 2012; 56
JW Alffenaar (50989_CR36) 2009; 49
UK Rohlwink (50989_CR45) 2017; 65
EE Evans (50989_CR26) 2022; 17
RF Jacobs (50989_CR34) 1992; 11
F Mota (50989_CR7) 2022; 13
AA Ordonez (50989_CR16) 2019; 5
P Phuapradit (50989_CR30) 1990; 53
Z Ahmad (50989_CR28) 2011; 55
ME Torok (50989_CR33) 2018; 103
AH Diacon (50989_CR27) 2010; 54
MG Whitfield (50989_CR41) 2015; 10
50989_CR9
EW Tucker (50989_CR53) 2018; 10
M Muller (50989_CR2) 2004; 48
50989_CR39
50989_CR38
KN Williams (50989_CR61) 2009; 53
G Lappin (50989_CR48) 2013; 9
NF Maranchick (50989_CR37) 2022; 13
CA Foss (50989_CR11) 2013; 208
AM Ginsberg (50989_CR29) 2009; 53
SK Jain (50989_CR3) 2018; 19
AD Heemskerk (50989_CR25) 2017; 65
AD Heemskerk (50989_CR42) 2016; 374
L Wihersaari (50989_CR44) 2022; 174
References_xml – volume: 2
  start-page: 445
  year: 1913
  end-page: 451
  ident: CR1
  article-title: Chemotherapeutics: scientific principles, methods, and results. Address in pathology to 17th International Congress of Medicine (London, 1913)
  publication-title: Lancet
– ident: CR22
– volume: 12
  start-page: e85307
  year: 2023
  ident: CR43
  article-title: Tryptophan metabolism determines outcome in tuberculous meningitis: a targeted metabolomic analysis
  publication-title: Elife
  doi: 10.7554/eLife.85307
– volume: 60
  start-page: 270
  year: 2016
  end-page: 277
  ident: CR59
  article-title: Contribution of oxazolidinones to the efficacy of novel regimens containing bedaquiline and pretomanid in a mouse model of tuberculosis
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.01691-15
– volume: 9
  start-page: e94462
  year: 2014
  ident: CR60
  article-title: Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0094462
– ident: CR39
– volume: 63
  start-page: e00021
  year: 2019
  end-page: 19
  ident: CR20
  article-title: Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of Tuberculosis
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.00021-19
– volume: 13
  year: 2022
  ident: CR37
  article-title: Cerebrospinal fluid concentrations of fluoroquinolones and carbapenems in tuberculosis meningitis
  publication-title: Front Pharm.
  doi: 10.3389/fphar.2022.1048653
– volume: 9
  start-page: e105222
  year: 2014
  ident: CR58
  article-title: Pharmacokinetics-pharmacodynamics analysis of bicyclic 4-nitroimidazole analogs in a murine model of tuberculosis
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0105222
– volume: 53
  start-page: 81
  year: 1990
  end-page: 82
  ident: CR30
  article-title: The blood/cerebrospinal fluid partitioning of pyrazinamide: a study during the course of treatment of tuberculous meningitis
  publication-title: J. Neurol. Neurosurg. Psychiatry
  doi: 10.1136/jnnp.53.1.81
– volume: 103
  start-page: 449
  year: 2018
  end-page: 457
  ident: CR33
  article-title: Suboptimal exposure to Anti-TB drugs in a TBM/HIV+ population is not related to antiretroviral therapy
  publication-title: Clin. Pharm. Ther.
  doi: 10.1002/cpt.646
– volume: 79
  start-page: 1797
  year: 2019
  end-page: 1803
  ident: CR10
  article-title: Pretomanid: First approval
  publication-title: Drugs
  doi: 10.1007/s40265-019-01207-9
– volume: 23
  year: 2022
  ident: CR17
  article-title: Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial
  publication-title: Trials
  doi: 10.1186/s13063-022-06772-1
– volume: 63
  year: 2024
  ident: CR21
  article-title: Linezolid does not improve bactericidal activity of rifampin-containing first-line regimens in animal models of TB meningitis
  publication-title: Int J. Antimicrob. Agents
  doi: 10.1016/j.ijantimicag.2023.107048
– volume: 54
  start-page: 3402
  year: 2010
  end-page: 3407
  ident: CR27
  article-title: Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.01354-09
– volume: 14
  start-page: 47
  year: 2015
  ident: CR23
  article-title: Antituberculosis drug resistance patterns in adults with tuberculous meningitis: results of haydarpasa-iv study
  publication-title: Ann. Clin. Microbiol. Antimicrob.
  doi: 10.1186/s12941-015-0107-z
– volume: 66
  year: 2022
  ident: CR46
  article-title: Superior efficacy of a TBI-166, bedaquiline, and pyrazinamide combination regimen in a murine model of tuberculosis
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/aac.00658-22
– volume: 59
  start-page: 1751
  year: 2018
  end-page: 1756
  ident: CR51
  article-title: Biodistribution and radiation dosimetry of (124)I-DPA-713, a PET radiotracer for macrophage-associated inflammation
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.117.207431
– ident: CR50
– volume: 351
  start-page: 1741
  year: 2004
  end-page: 1751
  ident: CR19
  article-title: Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa040573
– ident: CR9
– volume: 90
  start-page: 279
  year: 2010
  end-page: 292
  ident: CR31
  article-title: Cerebrospinal fluid concentrations of antituberculosis agents in adults and children
  publication-title: Tuberculosis
  doi: 10.1016/j.tube.2010.07.002
– volume: 10
  year: 2018
  ident: CR53
  article-title: Noninvasive (11)C-rifampin positron emission tomography reveals drug biodistribution in tuberculous meningitis
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.aau0965
– volume: 19
  start-page: 801
  year: 2020
  end-page: 818
  ident: CR49
  article-title: Phase 0/microdosing approaches: time for mainstream application in drug development?
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-020-0080-x
– volume: 17
  start-page: e0270201
  year: 2022
  ident: CR26
  article-title: Long term outcomes of patients with tuberculous meningitis: The impact of drug resistance
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0270201
– volume: 65
  start-page: 1298
  year: 2017
  end-page: 1307
  ident: CR45
  article-title: Biomarkers of cerebral injury and inflammation in pediatric tuberculous meningitis
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/cix540
– volume: 9
  start-page: 817
  year: 2013
  end-page: 834
  ident: CR48
  article-title: Microdosing and drug development: past, present and future
  publication-title: Expert Opin. Drug Metab. Toxicol.
  doi: 10.1517/17425255.2013.786042
– volume: 65
  start-page: 20
  year: 2017
  end-page: 28
  ident: CR25
  article-title: Clinical outcomes of patients with drug-resistant Tuberculous meningitis treated with an intensified antituberculosis regimen
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/cix230
– volume: 13
  start-page: 581
  year: 2017
  end-page: 598
  ident: CR4
  article-title: Tuberculous meningitis
  publication-title: Nat. Rev. Neurol.
  doi: 10.1038/nrneurol.2017.120
– volume: 19
  start-page: 521
  year: 2018
  end-page: 525
  ident: CR3
  article-title: Tuberculous meningitis: a roadmap for advancing basic and translational research
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-018-0119-x
– volume: 13
  start-page: 407
  year: 1997
  end-page: 484
  ident: CR56
  article-title: Physiological parameter values for physiologically based pharmacokinetic models
  publication-title: Toxicol. Ind. Health
  doi: 10.1177/074823379701300401
– volume: 21
  start-page: 450
  year: 2022
  end-page: 464
  ident: CR5
  article-title: Tuberculous meningitis: progress and remaining questions
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(21)00435-X
– volume: 53
  start-page: 3720
  year: 2009
  end-page: 3725
  ident: CR29
  article-title: Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.00106-09
– volume: 6
  start-page: 916
  year: 2020
  end-page: 921
  ident: CR15
  article-title: Radiosynthesis and biodistribution of (18)F-Linezolid in mycobacterium Tuberculosis-infected mice using positron emission tomography
  publication-title: ACS Infect. Dis.
  doi: 10.1021/acsinfecdis.9b00473
– volume: 26
  start-page: 529
  year: 2020
  end-page: 534
  ident: CR8
  article-title: Dynamic imaging in patients with Tuberculosis reveals heterogeneous drug exposures in pulmonary lesions
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-0770-2
– volume: 88
  start-page: 1835
  year: 2022
  end-page: 1844
  ident: CR57
  article-title: Population pharmacokinetics and target attainment analysis of linezolid in multidrug-resistant tuberculosis patients
  publication-title: Br. J. Clin. Pharm.
  doi: 10.1111/bcp.15102
– volume: 67
  year: 2023
  ident: CR47
  article-title: Next-generation diarylquinolines improve sterilizing activity of regimens with pretomanid and the novel oxazolidinone TBI-223 in a mouse tuberculosis model
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/aac.00035-23
– volume: 208
  start-page: 2067
  year: 2013
  end-page: 2074
  ident: CR11
  article-title: Noninvasive molecular imaging of Tuberculosis-associated inflammation with radioiodinated DPA-713
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jit331
– volume: 56
  start-page: 6284
  year: 2012
  end-page: 6290
  ident: CR52
  article-title: Noninvasive determination of 2-[18F]-fluoroisonicotinic acid hydrazide pharmacokinetics by positron emission tomography in Mycobacterium tuberculosis-infected mice
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.01644-12
– volume: 132
  start-page: e155851
  year: 2022
  ident: CR14
  article-title: High-dose rifampin improves bactericidal activity without increased intracerebral inflammation in animal models of Tuberculous meningitis
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI155851
– volume: 6
  start-page: 136
  year: 2021
  ident: CR18
  article-title: Study protocol for a phase 2A trial of the safety and tolerability of increased dose rifampicin and adjunctive linezolid, with or without aspirin, for HIV-associated tuberculous meningitis [LASER-TBM]
  publication-title: Wellcome Open Res.
  doi: 10.12688/wellcomeopenres.16783.1
– ident: CR40
– volume: 131
  start-page: e145107
  year: 2021
  ident: CR6
  article-title: Visualizing the dynamics of Tuberculosis pathology using molecular imaging
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI145107
– volume: 64
  start-page: 401
  year: 2017
  end-page: 407
  ident: CR24
  article-title: Long-term mortality of patients with Tuberculous meningitis in New York city: A cohort study
  publication-title: Clin. Infect. Dis.
– volume: 49
  start-page: 1080
  year: 2009
  end-page: 1082
  ident: CR36
  article-title: Pharmacokinetics of moxifloxacin in cerebrospinal fluid and plasma in patients with tuberculous meningitis
  publication-title: Clin. Infect. Dis.
  doi: 10.1086/605576
– volume: 10
  start-page: e0133869
  year: 2015
  ident: CR41
  article-title: A global perspective on pyrazinamide resistance: systematic review and meta-analysis
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0133869
– volume: 55
  start-page: 5485
  year: 2011
  end-page: 5492
  ident: CR54
  article-title: Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.05293-11
– volume: 59
  start-page: 1751
  year: 2018
  end-page: 1756
  ident: CR12
  article-title: Biodistribution and radiation dosimetry of (124)I-iodo-DPA-713, a PET radiotracer for macrophage-associated inflammation
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.117.207431
– volume: 59
  start-page: 642
  year: 2015
  end-page: 649
  ident: CR13
  article-title: Radioiodinated DPA-713 imaging correlates with bactericidal activity of Tuberculosis treatments in mice
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.04180-14
– volume: 16
  start-page: 144
  year: 2024
  ident: CR32
  article-title: Drug exposure and susceptibility of pyrazinamide correlate with treatment response in pyrazinamide-susceptible patients with multidrug-resistant tuberculosis
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics16010144
– ident: CR38
– volume: 62
  start-page: 519
  year: 2023
  end-page: 532
  ident: CR55
  article-title: Predictions of bedaquiline and pretomanid target attainment in lung lesions of tuberculosis patients using translational minimal physiologically based pharmacokinetic modeling
  publication-title: Clin. Pharmacokinet.
  doi: 10.1007/s40262-023-01217-7
– volume: 374
  start-page: 2188
  year: 2016
  end-page: 2189
  ident: CR42
  article-title: Therapy for tuberculous meningitis
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1507062
– volume: 53
  start-page: 1314
  year: 2009
  end-page: 1319
  ident: CR61
  article-title: Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.01182-08
– volume: 13
  year: 2022
  ident: CR7
  article-title: Dynamic (18)F-Pretomanid PET imaging in animal models of TB meningitis and human studies
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-35730-3
– volume: 48
  start-page: 1441
  year: 2004
  end-page: 1453
  ident: CR2
  article-title: Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.48.5.1441-1453.2004
– volume: 11
  start-page: 194
  year: 1992
  end-page: 198
  ident: CR34
  article-title: Intensive short course chemotherapy for tuberculous meningitis
  publication-title: Pediatr. Infect. Dis. J.
  doi: 10.1097/00006454-199203000-00004
– volume: 5
  start-page: 1996
  year: 2019
  end-page: 2002
  ident: CR16
  article-title: Radiosynthesis and PET bioimaging of (76)Br-Bedaquiline in a murine model of Tuberculosis
  publication-title: ACS Infect. Dis.
  doi: 10.1021/acsinfecdis.9b00207
– volume: 53
  start-page: 2882
  year: 2010
  end-page: 2891
  ident: CR35
  article-title: Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons
  publication-title: J. Med. Chem.
  doi: 10.1021/jm901858n
– volume: 174
  start-page: 1
  year: 2022
  end-page: 8
  ident: CR44
  article-title: Neurofilament light compared to neuron-specific enolase as a predictor of unfavourable outcome after out-of-hospital cardiac arrest
  publication-title: Resuscitation
  doi: 10.1016/j.resuscitation.2022.02.024
– volume: 55
  start-page: 239
  year: 2011
  end-page: 245
  ident: CR28
  article-title: PA-824 exhibits time-dependent activity in a murine model of tuberculosis
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.00849-10
– volume: 374
  start-page: 2188
  year: 2016
  ident: 50989_CR42
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1507062
– volume: 131
  start-page: e145107
  year: 2021
  ident: 50989_CR6
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI145107
– volume: 66
  year: 2022
  ident: 50989_CR46
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/aac.00658-22
– volume: 90
  start-page: 279
  year: 2010
  ident: 50989_CR31
  publication-title: Tuberculosis
  doi: 10.1016/j.tube.2010.07.002
– volume: 5
  start-page: 1996
  year: 2019
  ident: 50989_CR16
  publication-title: ACS Infect. Dis.
  doi: 10.1021/acsinfecdis.9b00207
– volume: 49
  start-page: 1080
  year: 2009
  ident: 50989_CR36
  publication-title: Clin. Infect. Dis.
  doi: 10.1086/605576
– volume: 79
  start-page: 1797
  year: 2019
  ident: 50989_CR10
  publication-title: Drugs
  doi: 10.1007/s40265-019-01207-9
– volume: 19
  start-page: 801
  year: 2020
  ident: 50989_CR49
  publication-title: Nat. Rev. Drug Discov.
  doi: 10.1038/s41573-020-0080-x
– volume: 63
  start-page: e00021
  year: 2019
  ident: 50989_CR20
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.00021-19
– volume: 53
  start-page: 2882
  year: 2010
  ident: 50989_CR35
  publication-title: J. Med. Chem.
  doi: 10.1021/jm901858n
– volume: 65
  start-page: 20
  year: 2017
  ident: 50989_CR25
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/cix230
– volume: 9
  start-page: e105222
  year: 2014
  ident: 50989_CR58
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0105222
– volume: 12
  start-page: e85307
  year: 2023
  ident: 50989_CR43
  publication-title: Elife
  doi: 10.7554/eLife.85307
– volume: 174
  start-page: 1
  year: 2022
  ident: 50989_CR44
  publication-title: Resuscitation
  doi: 10.1016/j.resuscitation.2022.02.024
– volume: 9
  start-page: 817
  year: 2013
  ident: 50989_CR48
  publication-title: Expert Opin. Drug Metab. Toxicol.
  doi: 10.1517/17425255.2013.786042
– volume: 55
  start-page: 5485
  year: 2011
  ident: 50989_CR54
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.05293-11
– volume: 13
  start-page: 581
  year: 2017
  ident: 50989_CR4
  publication-title: Nat. Rev. Neurol.
  doi: 10.1038/nrneurol.2017.120
– volume: 26
  start-page: 529
  year: 2020
  ident: 50989_CR8
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-0770-2
– ident: 50989_CR40
– volume: 11
  start-page: 194
  year: 1992
  ident: 50989_CR34
  publication-title: Pediatr. Infect. Dis. J.
  doi: 10.1097/00006454-199203000-00004
– volume: 59
  start-page: 642
  year: 2015
  ident: 50989_CR13
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.04180-14
– volume: 59
  start-page: 1751
  year: 2018
  ident: 50989_CR12
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.117.207431
– volume: 62
  start-page: 519
  year: 2023
  ident: 50989_CR55
  publication-title: Clin. Pharmacokinet.
  doi: 10.1007/s40262-023-01217-7
– volume: 53
  start-page: 3720
  year: 2009
  ident: 50989_CR29
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.00106-09
– volume: 208
  start-page: 2067
  year: 2013
  ident: 50989_CR11
  publication-title: J. Infect. Dis.
  doi: 10.1093/infdis/jit331
– volume: 17
  start-page: e0270201
  year: 2022
  ident: 50989_CR26
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0270201
– volume: 53
  start-page: 81
  year: 1990
  ident: 50989_CR30
  publication-title: J. Neurol. Neurosurg. Psychiatry
  doi: 10.1136/jnnp.53.1.81
– volume: 13
  start-page: 407
  year: 1997
  ident: 50989_CR56
  publication-title: Toxicol. Ind. Health
  doi: 10.1177/074823379701300401
– volume: 103
  start-page: 449
  year: 2018
  ident: 50989_CR33
  publication-title: Clin. Pharm. Ther.
  doi: 10.1002/cpt.646
– volume: 63
  year: 2024
  ident: 50989_CR21
  publication-title: Int J. Antimicrob. Agents
  doi: 10.1016/j.ijantimicag.2023.107048
– ident: 50989_CR38
– volume: 21
  start-page: 450
  year: 2022
  ident: 50989_CR5
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(21)00435-X
– volume: 2
  start-page: 445
  year: 1913
  ident: 50989_CR1
  publication-title: Lancet
– volume: 10
  year: 2018
  ident: 50989_CR53
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.aau0965
– volume: 6
  start-page: 136
  year: 2021
  ident: 50989_CR18
  publication-title: Wellcome Open Res.
  doi: 10.12688/wellcomeopenres.16783.1
– ident: 50989_CR22
– volume: 56
  start-page: 6284
  year: 2012
  ident: 50989_CR52
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.01644-12
– volume: 6
  start-page: 916
  year: 2020
  ident: 50989_CR15
  publication-title: ACS Infect. Dis.
  doi: 10.1021/acsinfecdis.9b00473
– volume: 9
  start-page: e94462
  year: 2014
  ident: 50989_CR60
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0094462
– ident: 50989_CR9
– volume: 351
  start-page: 1741
  year: 2004
  ident: 50989_CR19
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa040573
– volume: 64
  start-page: 401
  year: 2017
  ident: 50989_CR24
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/ciw763
– volume: 23
  year: 2022
  ident: 50989_CR17
  publication-title: Trials
  doi: 10.1186/s13063-022-06772-1
– volume: 67
  year: 2023
  ident: 50989_CR47
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/aac.00035-23
– volume: 55
  start-page: 239
  year: 2011
  ident: 50989_CR28
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.00849-10
– volume: 10
  start-page: e0133869
  year: 2015
  ident: 50989_CR41
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0133869
– volume: 13
  year: 2022
  ident: 50989_CR37
  publication-title: Front Pharm.
  doi: 10.3389/fphar.2022.1048653
– ident: 50989_CR50
– volume: 54
  start-page: 3402
  year: 2010
  ident: 50989_CR27
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.01354-09
– volume: 48
  start-page: 1441
  year: 2004
  ident: 50989_CR2
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.48.5.1441-1453.2004
– volume: 88
  start-page: 1835
  year: 2022
  ident: 50989_CR57
  publication-title: Br. J. Clin. Pharm.
  doi: 10.1111/bcp.15102
– volume: 19
  start-page: 521
  year: 2018
  ident: 50989_CR3
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-018-0119-x
– volume: 65
  start-page: 1298
  year: 2017
  ident: 50989_CR45
  publication-title: Clin. Infect. Dis.
  doi: 10.1093/cid/cix540
– volume: 13
  year: 2022
  ident: 50989_CR7
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-35730-3
– ident: 50989_CR39
  doi: 10.1007/s40262-024-01363-6
– volume: 16
  start-page: 144
  year: 2024
  ident: 50989_CR32
  publication-title: Pharmaceutics
  doi: 10.3390/pharmaceutics16010144
– volume: 53
  start-page: 1314
  year: 2009
  ident: 50989_CR61
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.01182-08
– volume: 59
  start-page: 1751
  year: 2018
  ident: 50989_CR51
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.117.207431
– volume: 132
  start-page: e155851
  year: 2022
  ident: 50989_CR14
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI155851
– volume: 14
  start-page: 47
  year: 2015
  ident: 50989_CR23
  publication-title: Ann. Clin. Microbiol. Antimicrob.
  doi: 10.1186/s12941-015-0107-z
– volume: 60
  start-page: 270
  year: 2016
  ident: 50989_CR59
  publication-title: Antimicrob. Agents Chemother.
  doi: 10.1128/AAC.01691-15
SSID ssj0000391844
Score 2.4757767
Snippet Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those...
Abstract Tuberculosis (TB) remains a leading cause of death, but antibiotic treatments for tuberculous meningitis, the deadliest form of TB, are based on those...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 6657
SubjectTerms 59
59/78
631/326/22/1290
64
64/60
692/308/575
692/420/254
82/58
96
96/21
96/63
Adult
Animals
Antibiotics
Antitubercular Agents - pharmacokinetics
Antitubercular Agents - therapeutic use
Bactericidal activity
Biodistribution
Brain
Brain - diagnostic imaging
Brain - metabolism
Brain injury
Compartments
Disease Models, Animal
Dosage
Drug resistance
Exposure
Female
Fluorine isotopes
Head injuries
Humanities and Social Sciences
Humans
Lung - diagnostic imaging
Lung - metabolism
Lungs
Male
Mass spectrometry
Mass spectroscopy
Meningitis
Mice
multidisciplinary
Multidrug resistance
Mycobacterium tuberculosis - drug effects
Partitioning
Penetration resistance
Pharmacokinetics
Positron emission
Positron emission tomography
Positron-Emission Tomography - methods
Rabbits
Science
Science (multidisciplinary)
Tissue Distribution
Tissues
Tuberculosis
Tuberculosis, Meningeal - diagnostic imaging
Tuberculosis, Meningeal - drug therapy
Tuberculosis, Multidrug-Resistant - diagnostic imaging
Tuberculosis, Multidrug-Resistant - drug therapy
SummonAdditionalLinks – databaseName: DOAJ Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bi9UwEA6yIPgi3q2uEsE3DZtbm_TRyy6LoPiwC_sWcqseOLTLaQvqr3eS9Bz3eH3xse0kDHPJzDTJNwg9h5gM_GlGvHOByKAYsbZrSM2U9t4xp2i6KPz-Q3N6Lt9d1BdXWn2lM2EFHrgI7ohxBxlv5MpBNHFC2s7FWinmdIL2pi6tvhDzrhRTeQ0WLZQucrklA4RHo8xrAkxCIEbqlsi9SJQB-3-XZf56WPKnHdMciE5uoZtLBolfFc5vo2uxv4Oul56SX--i7m3pMY8_Hp_hhM8E9oXLSfOpAPmvvsWAXWoNgW0f8BrcHU9Z_vCcrpAMMDOOXy6H9PdwxEOHp9nFjZ_Xw7gacdjMn8Z76Pzk-OzNKVmaKRBfSzYRG3nHay8pBMVQh0ZY7Z3kVAVw-iZw72nLmQ9KUcsDl11oReNFqy3U3rqx4j466Ic-PkQYBisVm9jJrpMR6qmaRk61t8pZq0WoENsK1vgFaTw1vFibvOMttCnKMKAMk5VhZIVe7MZcFpyNv1K_TvraUSaM7PwCLMcslmP-ZTkVOtxq2yyOOxoBUoCUmGpVoWe7z-ByaR_F9nGYMw1kXVyqukIPinHsOAG7yyBqFdJ7ZrPH6v6XfvU5w3ozBsltS5sKvdxa2A--_iyLR_9DFo_RDZ5cI2H9ykN0MG3m-ASyrck9zY71HUBTJko
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96Ivgifl_1lAi-abgkTZvsk_hxxyEoPtzBvoV89VxY2nXbgvrXO0mzPdaPe2ybhGlmJjOZTH6D0CuwyUCfYsRZ64nwkhFjmppUTCrnLLOSxovCn7_UZxfi07Ja5oBbn9Mqd2tiWqh952KM_LikYMilpEq-3XwnsWpUPF3NJTRuolsRuiymdMmlnGMsEf1cCZHvytBSHfcirQxgmAhYSrUgYs8eJdj-f_maf6dM_nFumszR6T10N_uR-N3E-PvoRmgfoNtTZcmfD1Hzcao0j7-enOOI0gRShqd882GC81_9Ch7bWCACm9bjNSg9HhIX4DleJOlgZBx-bLoYQ-xx1-BhtGHrxnXXr3rst-Nl_whdnJ6cfzgjuaQCcZVgAzGBN7xygoJp9JWvS6OcFZxKD6pfe-4cTDNzHibacM9F4xdl7cqFMrADV7UpH6ODtmvDIcLQWcpQh0Y0jQiwq6po4FQ5I60xqvQFYruJ1S7jjceyF2udzr1LpSdmaGCGTszQokCv5z6bCW3j2tbvI7_mlhEpO73otpc6K55m3MKOKXBpoacthWlsqKRkVsVRqS3Q0Y7bOqtvr6-ErUAv58-gePE0xbShG1Mb8L24kFWBnkzCMVMCcpeg1Aqk9sRmj9T9L-3qWwL3Zgxc3AWtC_RmJ2FXdP1_Lp5e_xvP0B0ehT5i-YojdDBsx_AcvKnBvkgq8xvttR6t
  priority: 102
  providerName: ProQuest
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1bi9UwEB7WFcEX8W51lQi-aTFJ0yZ91OMui6D4sAv7FnLreuDQLqctqL_eSdoeOboKPradCcNcOpPbNwCvMCejfIrlzlqfCy9ZbkxT5SWTyjnLrKTxovCnz9Xpufh4UV4cAF_uwqRD-wnSMv2ml9Nhb3uRQhozSo4pTtW5uAE3I3R79OpVtdqtq0TEcyXEfD-GFuoa1r0clKD6r6sv_zwm-dteaUpBJ3fhzlw7kneTtPfgILT34dbUTfL7A2g-TN3lyZfjMxKRmdCzyHTGfJgg_Nc_gic2NoUgpvVkg4FOhqR5fI6XRzocmYRvV11cN-xJ15BhtGHrxk3Xr3vit-Nl_xDOT47PVqf53EYhd6VgQ24Cb3jpBMV06EtfFUY5KziVHsO98tw5WnPmvJTUcM9F4-uickWtDM66VWWKR3DYdm14AgSZpQxVaETTiIAzqZIGTpUz0hqjCp8BWxSr3YwxHltdbHTa6y6Unoyh0Rg6GUOLDF7veK4mhI1_Ur-P9tpRRnTs9KLbXurZWzTjFmdJgUuLnLYQprGhlJJZFUelNoOjxdp6DtleF6gFLIapkhm83H3GYIs7KKYN3ZhosN7iQpYZPJ6cYycJ-l2CT8tA7bnNnqj7X9r11wTozRiWtTWtMnizeNgvuf6ui6f_R_4MbvMYBBHPVxzB4bAdw3OsqAb7IoXQT0O3HHc
  priority: 102
  providerName: Springer Nature
Title Dynamic PET reveals compartmentalized brain and lung tissue antibiotic exposures of tuberculosis drugs
URI https://link.springer.com/article/10.1038/s41467-024-50989-4
https://www.ncbi.nlm.nih.gov/pubmed/39143055
https://www.proquest.com/docview/3092977087
https://www.proquest.com/docview/3093172475
https://pubmed.ncbi.nlm.nih.gov/PMC11324906
https://doaj.org/article/12b747e27b024b34afbe5771b810380b
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZ2EWgviDuBURmJNwjEjhM7Dwh1pWWqtGmCVepb5FtGpSoZTSpt_HqOnaSoUHjgJVHiS6xz8Tkntr-D0GuwyTA-QUKtlAmZ4SSUskjDhHChtSKKR-6g8Nl5ejpj03ky30N9uqOOgPXO0M7lk5qtlu9uvt9-BIX_0B4ZF-9r5tUdrE0I5k9kIdtHh2CZuFPUs87d9zNznEFAw7qzM7ubHqG7UMsDYW2ZKo_ov8sN_XM35W9Lqt5STe6je52LiYetTDxAe7Z8iO60SSdvH6HiU5uEHl-ML7EDcAJC4HYretMi_S9-WIOVyx2BZWnwEuYD3HgGwbM7Y1JBz9jeXFfu92KNqwI3a2VXer2s6kWNzWp9VT9Gs8n4cnQadtkWQp0w0oTS0oImmkVgNU1i0lgKrRiNuIFZITVU6yijRBvOI0kNZYXJ4lTHmZAQnItUxk_QQVmV9hnC0Jhzm9qCFQWzEHAlkaWR0JIrKUVsAkR6wua6gyJ3GTGWuV8Sj0Xe8iUHvuSeLzkL0JtNm-sWiOOftU8cvzY1HYi2f1GtrvJOJ3NCFQRTlnIFLVXMZKFswjlRwvUaqQAd99zOe8HMY6AC-MyR4AF6tSkGnXQLLbK01drXAbeMMp4E6GkrHJuR9MIVILElNltD3S4pF9887jch4P1mURqgt72E_RrX32nx_P-_9AIdUacbDgKYHaODZrW2L8EJa9QA7fM5h6uYfB6gw-Fw-nUK95Px-cUXeDtKRwP_e2PgNfAnq7A2Dg
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9QwFLZKEYILYi2BAkaCE0R1HCf2HBAC2mpKF3GYSnMz3lJGGiXDJBGUH8Vv5NlJphqW3nqcie04ft9bvL0PoZfgk6F_IomN1jZmliexUkUeZwkXxuhEc-IvCh-f5ONT9mmaTTfQr-EujD9WOdjEYKhtZfwa-U5KwJFzTgR_t_gWe9Yov7s6UGh0sDh0599hyla_PdgF-b6idH9v8nEc96wCsclY0sTK0YJmhhHwDjazeaqE0YwSbgH9uaXGwJsSY-FdilrKCjtKc5OOhIJJqMhVCu1eQ9fB8RKvUXzKV2s6Ptu6YKy_m0NSsVOzYInAEcbgmcUoZmv-L9AE_Cu2_fuI5h_7tMH97d9Bt_u4Fb_vgHYXbbjyHrrRMVme30fFbsdsjz_vTbDPCgWoxt359qajD5j9dBZrT0iBVWnxHIwMboLU4be_uFJBy9j9WFR-zbLGVYGbVrulaedVPauxXbZn9QN0eiWD_RBtllXpHiEMlTl3uStYUTAHs7iMOEqEUVwrJVIboWQYWGn6_OaeZmMuwz57KmQnDAnCkEEYkkXo9arOosvucWnpD15eq5I-M3f4o1qeyV7RZUI1zNAc5Rpq6pSpQruM80QL3yrREdoepC17c1HLC3BH6MXqMSi6371RpavaUAZiPcp4FqGtDhyrngDuQuq2CIk12Kx1df1JOfsakoknCYTUI5JH6M2AsIt-_X8sHl_-Gc_RzfHk-EgeHZwcPkG3qFcAn0eYbaPNZtm6pxDJNfpZUB-Mvly1vv4GRzdcQg
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEIgXxJ3AACPBE0SNHSd2HxACumpjMO1hk_pmfMuoVCWlSQTjp_HrOHaSTuWytz22sR3H5zsX386H0AvwydA_QWKjtY2Z5SRWqsjjjHBhjCaaJ_6i8OfDfO-EfZxlsy30a7gL449VDjYxGGpbGb9GPkoTcOScJ4KPiv5YxNFk-nb5LfYMUn6ndaDT6CBy4M6-w_StfrM_AVm_pHS6e_xhL-4ZBmKTMdLEytGCZoYl4ClsZvNUCaMZTbgFTcgtNQbeSoyF9ypqKSvsOM1NOhYKJqQiVym0ewVd5WlGvI7xGV-v7_jM64Kx_p5OkopRzYJVAqcYg5cW45ht-MJAGfCvOPfv45p_7NkGVzi9hW72MSx-14HuNtpy5R10rWO1PLuLiknHco-Pdo-xzxAFCMfdWfemoxKY_3QWa09OgVVp8QIMDm4CAuC3v8RSQcvY_VhWfv2yxlWBm1a7lWkXVT2vsV21p_U9dHIpg30fbZdV6R4iDJU5d7krWFEwBzO6LHE0EUZxrZRIbYTIMLDS9LnOPeXGQoY991TIThgShCGDMCSL0Kt1nWWX6ePC0u-9vNYlfZbu8Ee1OpW90ktCNczWHOUaauqUqUK7jHOihW810RHaGaQte9NRy3OgR-j5-jEovd_JUaWr2lAG4j7KeBahBx041j0B3IU0bhESG7DZ6Ormk3L-NSQWJwTC63GSR-j1gLDzfv1_LB5d_BnP0HXQVPlp__DgMbpBPf59SmG2g7abVeueQFDX6KdBezD6ctnq-ht-MmB4
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dynamic+PET+reveals+compartmentalized+brain+and+lung+tissue+antibiotic+exposures+of+tuberculosis+drugs&rft.jtitle=Nature+communications&rft.au=Chen%2C+Xueyi&rft.au=Arun%2C+Bhavatharini&rft.au=Nino-Meza%2C+Oscar+J.&rft.au=Sarhan%2C+Mona+O.&rft.date=2024-08-14&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2041-1723&rft.volume=15&rft_id=info:doi/10.1038%2Fs41467-024-50989-4&rft_id=info%3Apmid%2F39143055&rft.externalDocID=PMC11324906
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2041-1723&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2041-1723&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2041-1723&client=summon